logo

Jazz Pharmaceuticals Plc (JAZZ)



Trade JAZZ now with
  Date
  Headline
1/19/2023 7:47:05 AM Jazz Pharma, Zymeworks Announce 84% Overall Survival At 18 Months From Phase 2 Trial Of Zanidatamab
12/21/2022 7:32:18 AM Jazz Confirms Opt-in And Advances Partnership With Zymeworks For Zanidatamab
10/19/2022 6:01:47 AM Jazz Pharma And Zymeworks Announce License Deal To Commercialize Zanidatamab, A HER2-Targeted Bispecific Antibody
8/18/2022 7:32:00 AM Jazz Pharma Begins Phase 3 Trial Of Epidiolex For Patients With Epilepsy With Myoclonic-Atonic Seizures
6/28/2022 7:36:46 AM Jazz : Phase 3 Trial Of Nabiximols Oromucosal Spray In Multiple Sclerosis Spasticity Fails To Meet Primary Endpoint
6/7/2022 7:32:43 AM Jazz Pharmaceuticals Presents Positive Data From Phase 2/3 Trial Of Rylaze In ALL Or Lymphoblastic Lymphoma At ASCO
5/9/2022 7:36:00 AM Jazz Pharma Completes U.S. Divestiture Of Sunosi To Axsome Therapeutics
4/7/2022 7:10:39 AM Jazz Pharma And Werewolf Therapeutics Announce Exclusive Global License And Collaboration Deal To Develop WTX-613
3/28/2022 6:12:19 AM Axsome Therapeutics Enters Agreement To Acquire Sunosi From Jazz Pharma
3/28/2022 6:02:42 AM Jazz Pharma To Divest Sunosi To Axsome Therapeutics
3/24/2022 7:34:32 AM Jazz : First Patient Enrolled In Phase 2 Trial Of Zepzelca Monotherapy On Metastatic Solid Tumors